9 meters biopharma, inc. (INNT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-3,603

-8,904

-9,221

-4,488

-4,434

-4,211

-775

-4,215

-14,959

-2,376

-2,451

-2,790

-3,987

-1,258

-1,834

-1,240

-1,881

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

276

593

900

852

526

-54

-3,131

-184

7,174

1,268

1,276

1,085

2,387

23

764

85

94

Accrued interest on convertible notes

81

-

-

-

35

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest on convertible notes

-

-

-

-

-

-

150

0

25

144

101

89

61

-

-

-

-

Amortization of debt discount

481

353

331

307

74

453

888

744

427

10

9

9

10

-

-

-

-

Depreciation

5

5

5

5

5

5

5

6

2

3

0

0

1

-

-

-

-

Beneficial conversion feature

-

-

-

-

-

0

0

0

3,077

0

0

0

0

-

-

-

-

Change in fair value of derivative liability

-338

-362

-229

-181

-101

-50

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-1,578

195

2,528

-1,812

-857

0

0

0

0

-

-

-

-

-

-

-

-

Warrant inducement expense

690

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Extinguishment of derivative liability

0

0

0

0

370

0

0

0

0

-

-

-

-

-

-

-

-

Amortization of deferred debt issuance costs and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

0

49

495

196

Amortization of trademark

-

-

-

-

-

-

-

-

-

-

-

-

-

33

33

32

33

Gain on settlement of customer refund

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Loss on extinguishment of debt

0

-49

0

49

-1,049

0

0

0

0

-

-

-

-

-

-

-

-

Provision for doubtful accounts

-

-

-

-

-

-

-

-

-

-

-

-

-

0

34

102

17

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-66

-226

-316

294

298

-65

293

-18

88

114

30

-40

50

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-72

-76

792

-279

Inventories

-

-

-

-

-

-

-

-

-

-

-

-

-

-684

760

538

-142

Prepaid expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

179

386

-4

-83

Accounts payable

1,185

833

350

-1,222

163

840

-464

1,322

-1,612

-320

502

548

15

-120

-1,078

-91

536

Accrued expenses

100

2,884

889

76

70

437

142

-5

-1,014

-546

-520

-217

741

-1,445

-441

587

-270

Accrued interest

0

0

0

0

-101

0

0

0

0

-

-

-

-

-

-

-

-

Customer refund

-

-

-

-

-

-

-

-

-

-

-

-

-

0

15

-25

0

Due to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-24

24

Net cash used in operating activities

-2,632

-3,223

-3,988

-6,517

-4,237

-2,408

-3,479

-2,313

-6,967

-1,931

-1,111

-1,232

-821

-

-

-

-

Cash flows from investing activities
Purchase of property and equipment

-

-

-

-

-

0

0

0

13

37

0

0

1

-

-

-

-

Loan payments from related party

-

-

-

-

-

0

0

0

75

0

0

0

0

-

-

-

-

Net cash provided by investing activities

0

-2

0

-9

0

-75

0

0

61

-37

0

0

-1

-

-

-

-

Cash flows from financing activities
Borrowings from convertible notes

2,500

0

0

0

5,000

0

0

0

3,345

0

0

0

0

-

-

-

-

Repayments of Debt

1,469

-

500

0

6,245

-

0

0

275

-

-

-

-

-

-

-

-

Proceeds from issuance of bridge financing

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

406

Proceeds from credit facility

-

-

-

-

-

-

-

-

-

-

-

-

-

60

0

189

392

Payments on credit facility

-

-

-

-

-

-

-

-

-

-

-

-

-

60

311

14

460

Payments of debt issuance costs

23

0

0

0

57

30

0

0

20

0

0

0

0

0

0

-75

132

Borrowings from convertible promissory notes

-

-

-

-

-

-

-

-

-

845

2,584

1,125

575

-

-

-

-

Payments of convertible notes

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,405

-747

Proceeds from issuance of preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,929

464

Proceeds from issuance of common stock and warrants

0

0

0

9,231

11,475

0

0

0

18,132

0

0

0

0

673

0

0

0

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Payment of deferred offering costs

300

0

0

876

168

51

0

0

1,655

0

0

0

0

-

-

-

-

Payment of stock subscription receivable

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Net cash provided by financing activities

707

-1,044

-485

8,370

10,003

100

928

0

19,527

845

2,584

1,125

575

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-1,925

-

-

-

5,765

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-2,313

12,621

-1,123

1,473

-107

-248

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,515

670

Net increase (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,517

2,818

110

-77

Supplemental disclosure of cash flow information
Cash paid during the period for interest

54

455

0

0

418

0

0

149

130

0

0

0

0

4

26

14

15

Supplemental disclosure of non-cash financing activities
Conversion of convertible notes and accrued interest to common stock

-

-

-

-

-

0

0

0

9,229

0

0

0

0

-

-

-

-

Assumption of liabilities from reverse recapitalization transaction

-

-

-

-

-

0

0

0

978

0

0

0

0

-

-

-

-

Warrants issued to placement agents

-

-

-

-

-

0

0

0

913

0

0

0

0

-

-

-

-

Non-cash addition of derivative liability

370

0

0

0

1,281

420

0

0

0

-

-

-

-

-

-

-

-

Non-cash addition of deferred offering costs

0

0

0

0

151

54

0

0

0

-

-

-

-

-

-

-

-

Non-cash addition of derivative liability

370

0

0

0

1,281

420

0

0

0

-

-

-

-

-

-

-

-

Non-cash addition of deferred offering costs

0

0

0

0

151

54

0

0

0

-

-

-

-

-

-

-

-

Exchange of debt for equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,520

3,164

297

59